

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
Shares on issue 105.8m
Market Capitalisation ~\$39.2m

BOARD & MANAGEMENT

Mr Mark Masterson
Non-Executive Chairman

Ms Jo Patterson
Chief Executive Officer

Mr Akash Bedi
Non-Executive Director

Mr George Livery
Non-Executive Director

Mr Patrice Malard
Non-Executive Director

Mr Simon O'Loughlin
Non-Executive Director

Mr Stephen Kelly
Company Secretary

CONTACT

Level 1, 377 New South Head Rd
Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

Bod records highest ever monthly sales of medicinal cannabis products

- **1,789 MediCabilis™ prescriptions filled during April 2021 – marks an 11% increase on March 2021 (March 2021 prescriptions: 1,617)**
- **Bod's products accounted for ~27% of the total Special Access Scheme Category B prescriptions filled across Australia in April 2021 (total: 6,682ⁱ)**
- **Takes total FY2021 units sold to 9,519 – marks a 138% increase on FY2020 (FY2020 prescriptions: ~4,000)**
- **13,624 MediCabilis™ units sold since first prescriptions in Q1 CY2019**
- **Medicinal cannabis sales growth expected to continue with introduction of new products and scale up of UK operations**

Sydney, Australia – 10 May 2021: Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited ("Bod", or "the Company") (ASX: BDA) is pleased to report that it has recorded its highest ever month of medicinal cannabis sales during April, filling a total of 1,789 MediCabilis™ prescriptions in Australia.

This is a major achievement for Bod and highlights an 11% increase on the previous month (March 2021 prescriptions: 1,617) and takes the total MediCabilis™ prescriptions filled in FY2021 to 9,519. Pleasingly, during April Bod filled ~27% of the total Special Access Scheme Category B prescriptions filled across Australia (total: 6,682). Total FY2021 prescriptions have currently increased 138% on FY2020 (FY2020 prescriptions: ~4,000), with the upward trend expected to continue.

64% of prescriptions dispensed during April 2021 were repeat prescriptions. This is a continuing trend allowing Bod to generate consistent and recurring revenue, and it further highlights patient and physician product satisfaction.

Growth is attributed to ongoing engagement and strong relationships with approved prescribers, educational initiatives with physicians and healthcare professionals, and Bod's Australia-wide clinical study to test the efficacy of MediCabilis™ when prescribed for conditions including anxiety, insomnia and Post Traumatic Stress Disorder (PTSD) (refer ASX announcement: 16 July 2020).




Image: Cumulative MediCabilis™ prescription sales

CEO Jo Patterson said: "MediCabilis™ volumes continue to grow at a very pleasing rate and the recent prescription sales growth further highlight Bod's ability to generate strong revenues across one of the Company's two core operating divisions."

"The Company continue to maintain a solid segment of the total Australian market through Special Access Scheme Category B. It is worth noting, that of the total Special Access Scheme approvals, not all result in a prescriptions being filled. Therefore, Bod's total market share may be potentially higher.

"The Company has a number of new products in the pipeline that will be launched imminently. We anticipate that the introduction of new products and scale up of operations across both business divisions will unlock considerable value for shareholders."




Image: Month on month MediCabilis™ sales FY2021

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

This announcement was authorised for release by the Board of Directors of Bod Australia Limited.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

ⁱ <https://www.tga.gov.au/medicinal-cannabis-role-tga>